publication . Article . 2020

COVID-19 Pneumonia in Patients with Chronic Myocarditis (Recurrent Infectious Immune): Specifics of the Diseases Course, the Role of Basic Therapy (Part 1)

O. V. Blagova; N. V. Varionchik; M. M. Beraia; V. A. Zaidenov; E. A. Kogan; N. D. Sarkisova; Nedostup Av;
Open Access English
  • Published: 02 Sep 2020 Journal: Racionalʹnaâ Farmakoterapiâ v Kardiologii, volume 16, issue 4, pages 550-556 (issn: 1819-6446, eissn: 2225-3653, Copyright policy)
  • Publisher: Stolichnaya Izdatelskaya Kompaniya
Patients with chronic myocarditis have a high risk of an unfavorable course of the novel coronavirus disease (COVID-19) due to the ability of the SARS-Cov-2 virus to independently cause acute myocarditis, to have a direct and cytokine-mediated cytopathic effect on the myocardium, as well as immunosuppressive therapy. At the same time, the features of the interaction of chronic myocarditis and COVID-19 have not been studied. The article describes a 31-year-old patient with a 10-year history of chronic recurrent infectious-immune myocarditis, who was on long-term immunosuppressive therapy (methylprednisolone and azathioprine in the past, then hydroxychloroquine). ...
Persistent Identifiers
free text keywords: covid-19, chronic myocarditis, bilateral pneumonia, immunosuppressive therapy, hydroxychloroquine, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701, Hydroxychloroquine, medicine.drug, medicine, Myocarditis, medicine.disease, Levofloxacin, business.industry, business, Exacerbation, Heart failure, Methylprednisolone, Internal medicine, medicine.medical_specialty, Coronavirus, medicine.disease_cause, Azathioprine
Any information missing or wrong?Report an Issue